Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study
Yanxin Chen(Central South University), Anwen Liu(Nanchang University)
Cited by 10
Related Papers
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
|Journal of Clinical Oncology|2022|177
Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
|Journal of Translational Medicine|2022|26
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
|Medicine Advances|2023|8
Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
|Thoracic Cancer|2023|5